Related Experiment Video
Updated: Jun 8, 2026
05:45
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations
1Department of Oral and Maxillofacial Surgery, School of Stomatology, Fourth Military Medical University, Xi’an, China. yangyaowu_1@sina.com
Journal of Vascular Surgery
|September 17, 2010
Summary
Bleomycin A5 sclerotherapy effectively treated cervicofacial lymphatic malformations (LMs) in 65 patients. This treatment showed high reduction rates for macrocystic and microcystic LMs with minimal complications and no recurrence.
Area of Science:
- Vascular Surgery
- Pediatric Surgery
- Dermatology
Background:
- Lymphatic malformations (LMs) are congenital vascular anomalies.
- Cervicofacial LMs present unique challenges in diagnosis and treatment.
- Sclerotherapy is a common treatment modality for LMs.
Purpose of the Study:
- To evaluate the efficacy and safety of bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations.
- To document clinical outcomes and patient data over a 3-year period.
Main Methods:
- Retrospective review of 65 patients treated between 2004 and 2007.
- Intralesional bleomycin A5 injection administered to 60 patients; 5 received combined resection and injection.
- Outcomes assessed via physical examination and Doppler ultrasonography.
Main Results:
- Significant size reduction achieved in macrocystic (81% >90% reduction) and microcystic (63% >90% reduction) LMs.
- Bleomycin A5 treatment involved 1-10 injections (mean 3.0) with doses ranging from 8-80 mg (mean 24.0 mg).
- Complications were minor, including oral mucosa ulceration and soft tissue atrophy; no recurrence observed.
Conclusions:
- Bleomycin A5 is a safe and effective intralesional agent for macrocystic LMs, superficial oral LMs, and localized microcystic lesions.
- Combined bleomycin A5 injection and resection may be necessary for extensive or diffuse LMs.
- Sclerotherapy with bleomycin A5 offers a promising treatment option for various lymphatic malformations.
